» Articles » PMID: 38771444

Meaning of ACR-TIRADS Recommendation in Favor of Follow-up Rather Than FNAC in Thyroid Nodules

Overview
Journal Updates Surg
Specialty General Surgery
Date 2024 May 21
PMID 38771444
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid Imaging Reporting and Data Systems (TIRADSs) have been largely diffused for their high accuracy in risk stratification of thyroid nodules (TNs) and their selection for fine-needle aspiration cytology (FNAC). The most popular TIRADSs are ACR-, EU-, and K-TIRADS, with some discrepancies each other. One major difference is that ACR-TIRADS includes a recommendation in favor of follow-up in TNs having a major diameter insufficient to indicate FNAC. The present study aimed to explore prevalence and significance of this recommendation. EU- and K-TIRADS were used as comparator. A retrospective series of thyroidectomies was searched according to a pre-defined protocol. The study period was 2019-2023. Preoperative ultrasound images were reviewed by radiologists blinded of clinical data. Matching of TIRADS and histology was performed later. Histology was the gold standard. The study series included 39 TNs classified as category 3, 4, or 5 and assessed for follow-up according to ACR-TIRADS. The overall cancer frequency was 25.6%, being 13% in category 3, 20% in category 4, and 83.3% in category 5. The category assessment according to ACR-, EU-, and K-TIRADS was not significantly different. EU-TIRADS indicated FNAC in 10 TNs of which two cancers and eight benign lesions. K-TIRADS recommended FNAC in 32 TNs of which seven cancers and 25 benign lesions. TNs assessed for follow-up according to ACR-TIRADS are cancer in one-fourth of cases. EU- and, especially, K-TIRADS allow us to select for FNAC cancers, with the burden of non-negligible frequency of unnecessary FNACs.

Citing Articles

Performance of ACR-TIRADS in assessing thyroid nodules does not vary according to patient age.

Leoncini A, Curti M, Ruinelli L, Gamarra E, Trimboli P Hormones (Athens). 2024; 23(4):667-674.

PMID: 39028415 PMC: 11519249. DOI: 10.1007/s42000-024-00585-4.

References
1.
Kim P, Suh C, Baek J, Chung S, Choi Y, Lee J . Unnecessary thyroid nodule biopsy rates under four ultrasound risk stratification systems: a systematic review and meta-analysis. Eur Radiol. 2020; 31(5):2877-2885. DOI: 10.1007/s00330-020-07384-6. View

2.
Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L . Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. J Clin Endocrinol Metab. 2018; 104(1):95-102. DOI: 10.1210/jc.2018-01674. View

3.
Sorrenti S, Dolcetti V, Radzina M, Bellini M, Frezza F, Munir K . Artificial Intelligence for Thyroid Nodule Characterization: Where Are We Standing?. Cancers (Basel). 2022; 14(14). PMC: 9315681. DOI: 10.3390/cancers14143357. View

4.
Castellana M, Piccardo A, Virili C, Scappaticcio L, Grani G, Durante C . Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma?. Cancer Cytopathol. 2020; 128(4):250-259. DOI: 10.1002/cncy.22235. View

5.
Trimboli P, Durante C . Ultrasound risk stratification systems for thyroid nodule: between lights and shadows, we are moving towards a new era. Endocrine. 2020; 69(1):1-4. DOI: 10.1007/s12020-020-02196-6. View